Recent developments in the clinical application of thyroid cancer biomarkers

Current Opinion in Oncology

Volumn 20, Issue 1, 2008, Pages 13-18

  Shibru, Daniel ^a   Chung, Ki Wook ^a   Kebebew, Electron ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Biomarkers; Diagnosis; Gene expression profiling; Prognosis; Thyroid cancer

Indexed keywords

BIOLOGICAL MARKER;

BENIGN TUMOR; COST EFFECTIVENESS ANALYSIS; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE MUTATION; GENOTYPE PHENOTYPE CORRELATION; HUMAN; NEEDLE BIOPSY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; THYROID CANCER; THYROID FOLLICLE CELL; THYROID TUMOR;

BIOPSY, FINE-NEEDLE; CARCINOMA, PAPILLARY, FOLLICULAR; GENE EXPRESSION PROFILING; GENOTYPE; HUMANS; MODELS, BIOLOGICAL; PHENOTYPE; PROGNOSIS; THYROID NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 36549045686     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/CCO.0b013e3282f27e49     Document Type: Review

References (49)

1. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin 2004; 54:8-29.
2. Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973-2002. Jama 2006; 295:2164-2167.
3. Kroll TG, Sarraf P, Pecciarini L, et al. PAX8-PPARgamma1 fusion oncogene in human thyroid carcinoma [corrected]. Science 2000; 289:1357-1360.
4. Gharib H, Goellner JR. Fine-needle aspiration biopsy of the thyroid: an appraisal. Ann Intern Med 1993; 118:282-289.
5. Castro MR, Gharib H. Thyroid fine-needle aspiration biopsy: progress, practice, and pitfalls. Endocr Pract 2003; 9:128-136.
6. Blansfield JA, Sack MJ, Kukora JS. Recent experience with preoperative fineneedle aspiration biopsy of thyroid nodules in a community hospital. Arch Surg 2002; 137:818-821.
7. Renshaw AA. Accuracy of thyroid fine-needle aspiration using receiver operator characteristic curves. Am J Clin Pathol 2001; 116:477-482.
8. Ravetto C, Colombo L, Dottorini ME. Usefulness of fine-needle aspiration in the diagnosis of thyroid carcinoma: a retrospective study in 37 895 patients. Cancer 2000; 90:357-363.
9. Carpi A, Ferrari E, De Gaudio C, et al. The value of aspiration needle biopsy in evaluating thyroid nodules. Thyroidology 1994; 6:5-9.
10. Baloch ZW, Fleisher S, LiVolsi VA, Gupta PK. Diagnosis of 'follicular neoplasm': a gray zone in thyroid fine-needle aspiration cytology. Diagn Cytopathol 2002; 26:41-44.
11. Baloch ZW, Hendreen S, Gupta PK, et al. Interinstitutional review of thyroid fine-needle aspirations: impact on clinical management of thyroid nodules. Diagn Cytopathol 2001; 25:231-234.
12. Yeh MW, Demircan O, Ituarte P, Clark OH. False-negative fine-needle aspiration cytology results delay treatment and adversely affect outcome in patients with thyroid carcinoma. Thyroid 2004; 14:207-215.
13. Tan YY, Kebebew E, Reiff E, et al. Does routine consultation of thyroid fine-needle aspiration cytology change surgical management? J Am Coll Surg 2007; 205:8-12.
14. Chung KW, Yang SK, Lee GK, et al. Detection of BRAFV600E mutation on fine needle aspiration specimens of thyroid nodule refines cyto-pathology diagnosis, especially in BRAF600E mutation-prevalent area. Clin Endocrinol (Oxf) 2006; 65:660-666.
15. Cohen Y, Rosenbaum E, Clark DP, et al. Mutational analysis of BRAF in fine needle aspiration biopsies of the thyroid: a potential application for the preoperative assessment of thyroid nodules. Clin Cancer Res 2004; 10:2761-2765.
16. Jin L, Sebo TJ, Nakamura N, et al. BRAF mutation analysis in fine needle aspiration (FNA) cytology of the thyroid. Diagn Mol Pathol 2006; 15:136-143.
17. Rowe LR, Bentz BG, Bentz JS. Utility of BRAF V600E mutation detection in cytologically indeterminate thyroid nodules. Cytojournal 2006; 3:10.
18. Salvatore G, Giannini R, Faviana P, et al. Analysis of BRAF point mutation and RET/PTC rearrangement refines the fine-needle aspiration diagnosis of papillary thyroid carcinoma. J Clin Endocrinol Metab 2004; 89:5175-5180.
19. Sapio MR, Posca D, Raggioli A, et al. Detection of RET/PTC, TRK and BRAF mutations in preoperative diagnosis of thyroid nodules with indeterminate cytological findings. Clin Endocrinol (Oxf) 2007; 66:678-683. This prospective study evaluated the accuracy of testing for mutations in clinical FNA biopsy samples. This study documented that this approach is technically feasible and can affect the initial surgical treatment.
20. Zhu Z, Ciampi R, Nikiforova MN, et al. Prevalence of RET/PTC rearrangements in thyroid papillary carcinomas: effects of the detection methods and genetic heterogeneity. J Clin Endocrinol Metab 2006; 91:3603-3610. This study demonstrated that the detection techniques used may account for the different rates of RET/PTC rearrangements reported in papillary thyroid cancer.
21. Nikiforov YE, Steward DL, Nikiforov MN, et al. Role of molecular testing for mutations in improving the fine needle aspiration (FNA) diagnosis of thyroid nodules (Proceedings of the 77th annual meeting of the American Thyroid Association) [abstract]. Thyroid 2006; 16:922.
22. Barden CB, Shister KW, Zhu B, et al. Classification of follicular thyroid tumors by molecular signature: results of gene profiling. Clin Cancer Res 2003; 9:1792-1800.
23. Finley DJ, Zhu B, Barden CB, Fahey TJ 3rd. Discrimination of benign and malignant thyroid nodules by molecular profiling. Ann Surg 2004; 240:425-436.
24. Mazzanti C, Zeiger MA, Costouros NG, et al. Using gene expression profiling to differentiate benign versus malignant thyroid tumors. Cancer Res 2004; 64:2898-2903.
25. Weber F, Shen L, Aldred MA, et al. Genetic classification of benign and malignant thyroid follicular neoplasia based on a three-gene combination. J Clin Endocrinol Metab 2005; 90:2512-2521.
26. Finley DJ, Arora N, Zhu B, et al. Molecular profiling distinguishes papillary carcinoma from benign thyroid nodules. J Clin Endocrinol Metab 2004; 89:3214-3223.
27. Aldred MA, Huang Y, Liyanarachchi S, et al. Papillary and follicular thyroid carcinomas show distinctly different microarray expression profiles and can be distinguished by a minimum of five genes. J Clin Oncol 2004; 22:3531-3539.
28. Kothapalli R, Yoder SJ, Mane S, Loughran TP Jr. Microarray results: how accurate are they? BMC Bioinformatics 2002; 3:22.
29. Lubitz CC, Ugras SK, Kazam JJ, et al. Microarray analysis of thyroid nodule fine-needle aspirates accurately classifies benign and malignant lesions. J Mol Diagn 2006; 8:490-498. This study suggested that thyroid FNA biospy samples may be analyzed using microarray analysis.
30. Kebebew E, Peng M, Reiff E, et al. Diagnostic and prognostic value of cell-cycle regulatory genes in malignant thyroid neoplasms. World J Surg 2006; 30:767-774.
31. Kebebew E, Peng M, Reiff E, et al. Diagnostic and prognostic value of angiogenesis-modulating genes in malignant thyroid neoplasms. Surgery 2005; 138:1102-1109.
32. Kebebew E, Peng M, Reiff E, et al. ECM1 and TMPRSS4 are diagnostic markers of malignant thyroid neoplasms and improve the accuracy of fine needle aspiration biopsy. Ann Surg 2005; 242:353-361.
33. Kebebew E, Peng M, Reiff E, McMillan A. Diagnostic and extent of disease multigene assay for malignant thyroid neoplasms. Cancer 2006; 106:2592-2597.
34. Xing M. BRAF mutation in thyroid cancer. Endocr Relat Cancer 2005; 12:245-262.
35. Xu X, Quiros RM, Gattuso P, et al. High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines. Cancer Res 2003; 63:4561-4567.
36. Nikiforova MN, Kimura ET, Gandhi M, et al. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab 2003; 88:5399-5404.
37. Trovisco V, Soares P, Preto A, et al. Type and prevalence of BRAF mutations are closely associated with papillary thyroid carcinoma histotype and patients' age but not with tumour aggressiveness. Virchows Arch 2005; 446:589-595.
38. Kim TY, Kim WB, Rhee YS, et al. The BRAF mutation is useful for prediction of clinical recurrence in low-risk patients with conventional papillary thyroid carcinoma. Clin Endocrinol (Oxf) 2006; 65:364-368.
39. Xing M, Westra WH, Tufano RP, et al. BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab 2005; 90:6373-6379.
40. Kim J, Giuliano AE, Turner RR, et al. Lymphatic mapping establishes the role of BRAF gene mutation in papillary thyroid carcinoma. Ann Surg 2006; 244:799-804.
41. Jo YS, Li S, Song JH, et al. Influence of the BRAF V600E mutation on expression of vascular endothelial growth factor in papillary thyroid cancer. J Clin Endocrinol Metab 2006; 91:3667-3670.
42. Namba H, Nakashima M, Hayashi T, et al. Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. J Clin Endocrinol Metab 2003; 88:4393-4397.
43. Fugazzola L, Mannavola D, Cirello V, et al. BRAF mutations in an Italian cohort of thyroid cancers. Clin Endocrinol (Oxf) 2004; 61:239-243.
44. Kim TY, Kim WB, Song JY, et al. The BRAF mutation is not associated with poor prognostic factors in Korean patients with conventional papillary thyroid microcarcinoma. Clin Endocrinol (Oxf) 2005; 63:588-593.
45. Liu RT, Chen YJ, Chou FF, et al. No correlation between BRAFV600E mutation and clinicopathological features of papillary thyroid carcinomas in Taiwan. Clin Endocrinol (Oxf) 2005; 63:461-466.
46. Puxeddu E, Moretti S, Elisei R, et al. BRAF(V599E) mutation is the leading genetic event in adult sporadic papillary thyroid carcinomas. J Clin Endocrinol Metab 2004; 89:2414-2420.
47. Sedliarou I, Saenko V, Lantsov D, et al. The BRAFT1796A transversion is a prevalent mutational event in human thyroid microcarcinoma. Int J Oncol 2004; 25:1729-1735.
48. Kebebew E, Weng J, Bauer J, et al. The prevalence and prognostic value of BRAF mutation in thyroid cancer. Ann Surg 2007; 246:466-471.
49. Lee JH, Lee ES, Kim YS. Clinicopathologic significance of BRAF V600E mutation in papillary carcinomas of the thyroid: a meta-analysis. Cancer 2007; 110:38-46.